High B7-H3 expression is linked to increased risk of prostate cancer progression
Standard
High B7-H3 expression is linked to increased risk of prostate cancer progression. / Bonk, Sarah; Tasdelen, Pinar; Kluth, Martina; Hube-Magg, Claudia; Makrypidi-Fraune, Georgia; Möller, Katharina; Höflmayer, Doris; Dwertmann Rico, Sebastian; Büscheck, Franziska; Minner, Sarah; Heinzer, Hans; Graefen, Markus; Hinsch, Andrea; Luebke, Andreas M; Dum, David; Uhlig, Ria; Schlomm, Thorsten; Sauter, Guido; Simon, Ronald; Weidemann, Sören A.
In: PATHOL INT, Vol. 70, No. 10, 10.2020, p. 733-742.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - High B7-H3 expression is linked to increased risk of prostate cancer progression
AU - Bonk, Sarah
AU - Tasdelen, Pinar
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Makrypidi-Fraune, Georgia
AU - Möller, Katharina
AU - Höflmayer, Doris
AU - Dwertmann Rico, Sebastian
AU - Büscheck, Franziska
AU - Minner, Sarah
AU - Heinzer, Hans
AU - Graefen, Markus
AU - Hinsch, Andrea
AU - Luebke, Andreas M
AU - Dum, David
AU - Uhlig, Ria
AU - Schlomm, Thorsten
AU - Sauter, Guido
AU - Simon, Ronald
AU - Weidemann, Sören A
N1 - © 2020 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
PY - 2020/10
Y1 - 2020/10
N2 - B7-H3 is a member of the B7 superfamily of immune checkpoint molecules. B7-H3 up regulation has been linked to cancer development and progression in many tumors including prostate cancer. To clarify the potential utility of B7-H3 as a prognostic biomarker, B7-H3 expression was analyzed by immunohistochemistry in more than 17 000 prostate cancers. Normal prostatic glands were largely B7-H3 negative, while membranous B7-H3 immunostaining was seen in 47.0% of analyzed cancers. B7-H3 immunostaining was weak in 12.3%, moderate in 21.1% and strong in 13.5% of cases. High B7-H3 expression was associated with pT, Gleason score, lymph node metastasis, high Ki67 labeling index and early prostate-specific antigen recurrence (P < 0.0001 each). High B7-H3 expression was also linked to high androgen receptor expression and TMPRSS2:V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusions (P < 0.0001 each). Multivariate analyses showed a strong independent prognostic impact of high B7-H3 expression in all cancers and in the ERG negative subgroup. Comparison with previously analyzed frequent chromosomal deletions revealed a close association with Phosphatase and Tensin Homolog deletions. Analysis of B7-H3, alone or in combination with other markers, might be of clinical utility, especially in the subgroup of ERG negative prostate cancers.
AB - B7-H3 is a member of the B7 superfamily of immune checkpoint molecules. B7-H3 up regulation has been linked to cancer development and progression in many tumors including prostate cancer. To clarify the potential utility of B7-H3 as a prognostic biomarker, B7-H3 expression was analyzed by immunohistochemistry in more than 17 000 prostate cancers. Normal prostatic glands were largely B7-H3 negative, while membranous B7-H3 immunostaining was seen in 47.0% of analyzed cancers. B7-H3 immunostaining was weak in 12.3%, moderate in 21.1% and strong in 13.5% of cases. High B7-H3 expression was associated with pT, Gleason score, lymph node metastasis, high Ki67 labeling index and early prostate-specific antigen recurrence (P < 0.0001 each). High B7-H3 expression was also linked to high androgen receptor expression and TMPRSS2:V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusions (P < 0.0001 each). Multivariate analyses showed a strong independent prognostic impact of high B7-H3 expression in all cancers and in the ERG negative subgroup. Comparison with previously analyzed frequent chromosomal deletions revealed a close association with Phosphatase and Tensin Homolog deletions. Analysis of B7-H3, alone or in combination with other markers, might be of clinical utility, especially in the subgroup of ERG negative prostate cancers.
U2 - 10.1111/pin.12999
DO - 10.1111/pin.12999
M3 - SCORING: Journal article
C2 - 32776718
VL - 70
SP - 733
EP - 742
JO - PATHOL INT
JF - PATHOL INT
SN - 1320-5463
IS - 10
ER -